The NR superfamily comprises 48 transcription factors in humans that control a plethora of
gene network programs involved in a wide range of physiologic processes. This review will …

Super-enhancers are large, densely concentrated swaths of enhancers that regulate genes
critical for cell identity. Tumorigenesis is accompanied by changes in the super-enhancer …

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish
a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and …

Numerous cancers, including prostate cancer (PCa), are addicted to transcription programs
driven by specific genomic regions known as super-enhancers (SEs). The robust …

Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy.
The development of new CRPC treatment strategies is strongly impeded by the scarcity of …

The androgen receptor (AR) and estrogen receptor alpha (ERα) are steroid receptor
transcription factors with critical roles in the development and progression of prostate and …

Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate
cancer (CRPC) with defects in homologous recombination (HR) DNA repair. New treatments …

Simple Summary There is a widespread push toward more biologically relevant pre-clinical
models of prostate cancer that can improve the discovery and translation of new drugs and …

Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice.
Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking …

Metastatic prostate cancer (mPC) has a poor prognosis, and new treatment strategies are
currently being offered for patients in clinical practice, but mPC is still incurable. A …